United States · FDA National Drug Code directory
Ondansetron
A source-listed medicine record.
Factual source checks only. This page is not a clinically reviewed monograph. Historical or discontinued records may be included; listing does not confirm approval, current availability or pharmacy stock.
Medicine identity
- Source reference
- 76420-217_2eaaa08a-db13-8991-e063-6294a90ac450
- Product NDC
- 76420-217
- Form
- TABLET, ORALLY DISINTEGRATING
- Composition / generic term
- Ondansetron
- Labeler
- Asclemed USA, Inc.
- Marketing category
- ANDA
- Marketing start / end (source format)
- 20100412
- Source listing expiry
- 20261231
Source-listed ingredients
- ONDANSETRON — 4 mg/1
These values do not establish equivalence or a dose recommendation.
Packages
- 4 TABLET, ORALLY DISINTEGRATING in 1 BOTTLE (76420-217-04) · 76420-217-04
- 6 TABLET, ORALLY DISINTEGRATING in 1 BOTTLE (76420-217-06) · 76420-217-06
- 10 TABLET, ORALLY DISINTEGRATING in 1 BOTTLE (76420-217-10) · 76420-217-10
- 20 TABLET, ORALLY DISINTEGRATING in 1 BOTTLE (76420-217-20) · 76420-217-20
- 3 BLISTER PACK in 1 CARTON (76420-217-30) / 10 TABLET, ORALLY DISINTEGRATING in 1 BLISTER PACK · 76420-217-30
Source and coverage
Open FDA National Drug Code directory →
Snapshot retrieved: 2026-09-17. This is the acquisition date, not a medical review date.
Clinical information, images and comparisons appear only when separately reviewed for this record. Coverage may be incomplete. Ask a pharmacist or clinician about your treatment.
Browse United States records →